Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureHanqing Qian, Baorui Liu, Xiqun Jiang
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases
10.1097/00003086-199101000-00002 · 1991
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
10.1126/science.1076514 · 2002
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
10.1016/s0140-6736(16)00561-4 · 2016
Pembrolizumab versus ipilimumab in advanced melanoma
10.1056/nejmoa1503093 · 2015
Oncology meets immunology: the cancer-immunity cycle
10.1016/j.immuni.2013.07.012 · 2013
Nanoparticulate immunotherapy for cancer
10.1016/j.jconrel.2015.09.062 · 2015
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
10.1073/pnas.1320318110 · 2013
Regulatory circuits of T cell function in cancer
10.1038/nri.2016.80 · 2016
The role of myeloid cells in cancer therapies
10.1038/nrc.2016.54 · 2016
Immune cell promotion of metastasis
10.1038/nri3789 · 2015
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
10.1084/jem.20101956 · 2011
Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity
10.1158/0008-5472.can-13-0875 · 2013
Cancer immunotherapy comes of age
10.1038/nature10673 · 2011
Neutralizing tumor-promoting chronic inflammation: a magic bullet
10.1126/science.1232227 · 2013
Targeting myeloid cells using nanoparticles to improve cancer immunotherapy
10.1016/j.addr.2014.09.007 · 2015
Engineering synthetic vaccines using cues from natural immunity
10.1038/nmat3775 · 2013
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
10.1038/nri2868 · 2010
Synthetic nanovaccines for immunotherapy
10.1016/j.jconrel.2017.03.033 · 2017
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
10.1038/nbt1332 · 2007
In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles
10.1016/j.jconrel.2006.01.006 · 2006
Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose
10.1073/pnas.1313152110 · 2013
Nanoparticles target distinct dendritic cell populations according to their size
10.1002/eji.200737984 · 2008
Engineered materials for cancer immunotherapy
10.1016/j.nantod.2015.06.007 · 2015
Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study
10.1016/j.jconrel.2014.07.040 · 2014
CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses
10.1016/j.biomaterials.2014.10.053 · 2015
Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype
10.1016/j.biomaterials.2012.03.041 · 2012
Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice
10.1016/j.jconrel.2012.06.015 · 2012
Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery
10.1016/j.biomaterials.2011.01.067 · 2011
Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy
10.1038/nbt.3071 · 2015
Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation
10.1016/j.vaccine.2010.09.077 · 2010
pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides
10.1021/nn305466z · 2013
Structure-based programming of lymph-node targeting in molecular vaccines
10.1038/nature12978 · 2014
Immune system targeting by biodegradable nanoparticles for cancer vaccines
10.1016/j.jconrel.2013.03.010 · 2013
Infection-mimicking materials to program dendritic cells in situ
10.1038/nmat2357 · 2009
Nanoparticle-Based Manipulation of antigen-presenting cells for cancer immunotherapy
10.1002/smll.201501284 · 2015
Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery
10.1021/nl500618u · 2014
Adjuvant-loaded subcellular vesicles derived from disrupted cancer cells for cancer vaccination
10.1002/smll.201600061 · 2016
Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth
10.1016/j.biomaterials.2015.09.031 · 2016
Designer vaccine nanodiscs for personalized cancer immunotherapy
10.1038/nmat4822 · 2017
Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11
10.1016/j.cellimm.2011.04.005 · 2011
Immunoengineering: how nanotechnology can enhance cancer immunotherapy
10.1016/j.cell.2015.03.037 · doi-reference
Human cytotoxic T-lymphocyte membrane-camouflaged nanoparticles combined with low-dose irradiation: a new approach to enhance drug targeting in gastric cancer
10.2147/ijn.s126016 · doi-reference
Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination
10.1002/ijc.28418 · doi-reference
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
10.1038/nnano.2017.113 · doi-reference
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
10.1016/s1470-2045(15)00007-8 · doi-reference
Radiotherapy and immunotherapy: a beneficial liaison?
10.1038/nrclinonc.2016.211 · doi-reference
Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy
10.1038/ncomms12499 · doi-reference
Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer
10.1021/acsnano.7b00715 · doi-reference
Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles
10.1021/nn5002112 · doi-reference
Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
10.1038/ncomms13193 · doi-reference
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
10.1038/nm.4200 · doi-reference
Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma
10.1158/1078-0432.ccr-15-2657 · doi-reference
Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling
10.1016/j.cell.2016.03.031 · doi-reference
Nanoscale artificial antigen presenting cells for T cell immunotherapy
10.1016/j.nano.2013.06.015 · doi-reference
A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells
10.1038/mt.2008.11 · doi-reference
Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation
10.1002/smll.201402369 · doi-reference
A carbon nanotube-polymer composite for T-cell therapy
10.1038/nnano.2014.154 · doi-reference
Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity
10.1021/nn405520d · doi-reference
6-Thioguanine-loaded polymeric micelles deplete myeloid-derived suppressor cells and enhance the efficacy of T cell immunotherapy in tumor-bearing mice
10.1007/s00262-015-1702-8 · doi-reference
Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection
10.1073/pnas.92.14.6254 · doi-reference
Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment
10.1016/bs.acr.2015.04.002 · doi-reference
Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy
10.1038/nnano.2017.69 · doi-reference
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
10.1038/nnano.2017.57 · doi-reference
Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing
10.1002/adhm.201500089 · doi-reference
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
10.1038/s41551-016-0011 · doi-reference
Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy
10.1021/ja102414t · doi-reference
Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages
10.1021/acsnano.7b05465 · doi-reference
Efficient identification of murine M2 macrophage peptide targeting ligands by phage display and next-generation sequencing
10.1021/acs.bioconjchem.5b00344 · doi-reference
Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival
10.1073/pnas.1312197110 · doi-reference
Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles
10.1021/mp400216r · doi-reference
Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy
10.1155/2011/565187 · doi-reference
In vivo targeting of intratumor regulatory T cells using PEG-modified single-walled carbon nanotubes
10.1021/bc400070q · doi-reference
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
10.1073/pnas.0806075105 · doi-reference
The immune contexture in human tumours: impact on clinical outcome
10.1038/nrc3245 · doi-reference
How regulatory T cells work
10.1038/nri2343 · doi-reference
Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy
10.1038/nmat3355 · doi-reference
Transforming growth factor-beta and the immune response: implications for anticancer therapy
10.1158/1078-0432.ccr-07-1157 · doi-reference
Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment
10.1016/j.nantod.2014.10.001 · doi-reference
Bimodal tumor-targeting from microenvironment responsive hyaluronan layer-by-layer (LbL) nanoparticles
10.1021/nn502861t · doi-reference
Bioresponsive mesoporous silica nanoparticles for triggered drug release
10.1021/ja206998x · doi-reference